Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
- May‐Lynn Huang, A. Peer, +6 authors J. Jonkman
- Clinical pharmacology and therapeutics
- 1 September 1993
It is concluded that risperidone metabolic polymorphism on increased plasma prolactin is minimal and that the active moiety is clinically relevant. Expand
Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells.
- W. Wouters, J. van Dun, A. Dillen, M. Coene, W. Cools, R. De Coster
- Biology, Medicine
- Cancer research
- 15 May 1992
It is concluded that the enhancement by liarozole of the antiproliferative effects of retinoic acid on MCF-7 human breast cancer cells is probably due to inhibition of retinoid metabolism in cancer treatment. Expand
The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats
- S. Kapur, X. Langlois, P. Vinken, A. Megens, R. De Coster, J. Andrews
- Psychology, Medicine
- Journal of Pharmacology and Experimental…
- 1 September 2002
Results indicate that dissociation between central and peripheral D2 receptor occupancy is a major determinant of the degree of prolactin elevation observed at therapeutic doses. Expand
Aromatase inhibition by the antifungal ketoconazole.
- W. Wouters, R. De Coster, N. Goeminne, D. Beerens, J. van Dun
- Chemistry, Medicine
- Journal of steroid biochemistry
It is concluded that ketoconazole is not a compound of choice for clinical use as an aromatase inhibitor because it only marginally lowered plasma levels of estradiol-17 beta. Expand
Endocrinological effects of single daily ketoconazole administration in male beagle dogs.
The results confirm that a high therapeutic dose of ketoconazole, given orally once a day, transiently inhibits in vivo the 17-20 lyase enzyme of the testis, without modifying basal cortisol and oestradiol-17 beta plasma concentrations and that enzymatic inhibition still occurs after daily treatment for up to 2 weeks but remains transient and parallels the resorption profile of the drug. Expand
Itraconazole: pharmacologic studies in animals and humans.
- H. van Cauteren, J. Heykants, R. De Coster, G. Cauwenbergh
- Reviews of infectious diseases
Several pharmacologic studies of itraconazole, an orally active antifungal triazole, were conducted in humans and animals. In dogs and rats, no significant toxic effects were seen at doses of up to… Expand
Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats.
- D. Vanderschueren, E. van Herck, J. Nijs, A. Ederveen, R. De Coster, R. Bouillon
- Medicine, Chemistry
- 1 June 1997
Treatment with the aromatase inhibitor VOR impairs body weight gain and skeletal modeling and decreases bone mineral density in growing 6-week-old male Wistar rats. Expand
Comparative effects of ketoconazole on rat, dog and human testicular steroidogenesis.
- R. De Coster, M. Coene, C. van Camp, K. van Camp, D. Beerens, W. Cools
- Biology, Medicine
- Journal of enzyme inhibition
The results showed that ketoconazole inhibited androgen biosynthesis at lower concentrations in dispersed human testicular cells than in canine and rat cells and rat and dog cells whereas only the 17,20-lyase activity and then the 17-hydroxylation was affected in human cells. Expand
Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.
Inhibition of the growth of several androgens-dependent and, chiefly, androgen-independent Dunning prostate carcinoma sublines that differ widely in their histological degree of differentiation and growth rate suggests that liarozole may be a suitable agent for evaluation in second line treatment of hormone refractory prostate carcinomas in patients who relapse after androgen ablation. Expand
Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
- C. Bowden, S. Voina, R. Woestenborghs, R. De Coster, J. Heykants
- Biology, Medicine
- The Journal of pharmacology and experimental…
- 1 August 1992
Risperidone was 3 to 5 times more potent than the classical D2 receptor antagonist haloperidol in stimulating rat prolactin levels in vivo and 9-hydroxy-risperidones, identified as a major metabolite in the S-9 conditioned media, was equipotent to risperid one in modulating prolact in release in vitro. Expand